Biotech Buzz Vol. 12: Heat resistant plastics, come snail therapies and Ozempic factory establishment
Robert Naughton
?????? ???? ??????????: Recombinant Antibodies and Proteins | ELISA Kits | Cytokines GMP | Viral Antigens | CAR-T, Oncology, Drug Discovery, Immunotherapy, Diagnostics Support | Antibody Development and Engineering | CRO
Hey there, it’s Rob! I’m passionate about everything biotech so I always try to stay in the loop. Whether it’s a ground breaking cancer discovery or an exciting merger, I’ve struggled to keep up with all the news. So, I thought, why not put together a little newsletter? Maybe others are facing the same challenge.
I hope you find this informative, and if you have any suggestions or comments, feel free to share! ??
Big Announcement
We're excited to host the “???????????????????? ?????? ?????????????????????????? ???? ?????????????????????? ???????????????? ??????????????????????” ??????????????????", where we'll dive into the fast-growing therapeutic antibody market.
With over 150 antibody drugs now approved or under review globally, this event is a must for anyone interested in the future of antibody therapeutics.Expect to engage with industry leaders and experts as we explore the latest innovations, challenges, and opportunities in this dynamic field.
This is a unique chance to connect, learn, and potentially spark new collaborations. Expert speakers include Kai-Michael Toellner, Marie Bonnet-Di Placido, Jennifer Fleming, Helen Graves and our very own Yu-Chih Lin, Ph.D.
?? Date: Thursday, September 5, 2024
?? Location: Babraham Research Campus, Cambridge, UK
?? Hosted by: Sino Biological, Inc., in partnership with One Nucleus
Whether you're a researcher or industry expert, this event promises valuable insights and networking opportunities and is totally ???????? ????
To register your interest or simply know more, follow the link below! Let’s push the boundaries of therapeutic antibody development together!
Quick, there's not many seats left!
领英推荐
Korean researchers engineered E. coli to produce biodegradable polymers that mimic the strength and stability of industrial plastics like PET and polystyrene. By constructing novel metabolic pathways, the bacteria now create ring-like structures, opening doors for drug delivery and more.
Researchers from the University of Utah found that a venomous cone snail's toxin mimics the human hormone somatostatin, which regulates blood sugar and hormone levels. This highly stable and specific toxin could inspire the development of more effective drugs for diabetes and hormone disorders, offering fewer side effects and longer-lasting benefits.
Researchers are using Explainable AI (XAI) to enhance antibiotic discovery by uncovering what AI models prioritize in drug molecules. This approach has revealed new insights, such as overlooked molecular structures, potentially leading to the development of more effective antibiotics.
百时美施贵宝 ’s upcoming schizophrenia drug KarXT faces stiff competition from AbbVie ’s emraclidine, which offers potential advantages like once-daily dosing and fewer side effects. The growing market for innovative treatments is becoming increasingly competitive.
The FDA has approved 强生公司 ’s Rybrevant and Lazcluze for treating EGFR-mutated non-small cell lung cancer. This combo, which outperformed 阿斯利康 ’s Tagrisso in trials, is the first chemotherapy-free regimen to show such superiority.
诺和诺德 is investing $220 million to build a new 8,000-square-meter factory in K?ge, Denmark. The facility will enhance production and storage for drugs like Ozempic and Wegovy, meeting rising demand and supporting chronic disease treatments.
That's all folks! Thanks for reading and stay tuned for next weeks newsletter.